Claudia Bica

Claudia Bica

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2015 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
MBMaiquidieli Dal Berto
Maiquidieli Dal Berto
CBClaudia Bica
Claudia Bica
GSGustavo Pereira de Sá
Gustavo Pereira de Sá
FBFernanda Barbisan
Fernanda Barbisan
VAVerônica Farina Azzolin
Verônica Farina Azzolin
ICIvana Beatrice Beatrice Mânica Mânica Da Cruz
Ivana Beatrice Beatrice Mânica Mânica Da Cruz

1 January 2022 in Revista Brasileira de Enfermagem
Verified
Journal Article
Open access
JSJuliane de Souza Scherer
Juliane de Souza Scherer
JPJéssica Silveira Pereira
Jéssica Silveira Pereira
MDMariana Severo Debastiani
Mariana Severo Debastiani
CBClaudia Bica
Claudia Bica
Objective: To analyze the critical alarms predictors of clinical deterioration/sepsis for clinical decision making in patients admitted to a reference hospital complex. Methods: An observational retrospective cohort study. The Machine Learning (ML) tool, Robot Laura®, scores changes in vital parameters and lab tests, classifying them by severity. Inpatients and patients over 18 years of age were included. Results: A total of 122,703 alarms were extracted from the platform, classified as 2 to 9. The pre-selection of critical alarms (6 to 9) indicated 263 urgent alerts (0.2%), from which, after filtering exclusion criteria, 254 alerts were delimited for 61 inpatients. Patient mortality from sepsis was 75%, of which 52% was due to sepsis related to the new coronavirus. After the alarms were answered, 82% of the patients remained in the sectors. Conclusions: Far beyond technology, ML models can speed up assertive clinical decisions by nurses, optimizing time and specialized human resources.

1 January 2020 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
JSJéssica Niederauer Leote da Silva
Jéssica Niederauer Leote da Silva
ARAlana Durayski Ranzi
Alana Durayski Ranzi
CCCaroline Trainotti Carvalho
Caroline Trainotti Carvalho
TSTales Vicente Scheide
Tales Vicente Scheide
YSYuri Thomé Machado Strey
Yuri Thomé Machado Strey
CBClaudia Bica
Claudia Bica

1 April 2019 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
ASAniúsca Vieira dos Santos
Aniúsca Vieira dos Santos
GSGiovana Tavares dos Santos
Giovana Tavares dos Santos
RBRosicler Luzia Brackmann
Rosicler Luzia Brackmann
JPJoão Carlos Prolla
João Carlos Prolla
CBClaudia Bica
Claudia Bica
Abnormalities in the cervix, when identified early by Pap smear, can be treated in the early stages or in the precursorstages of the neoplasia, which may increase the chances of regression of the lesion. The aim to verify the rate of cervicalabnormalities and to evaluate the risk of progression or regression associated with age and cytological diagnosis.Methods: The study was conducted in a referral hospital in Southern Brazil, based on the results of pathology andcytopathology laboratory tests of uterine cervix. The historical cohort included patients with an abnormal cytologydiagnosis in the period from January 2010 to December 2014, followed until July 2016. Results: A total of 42,389cervical smears were analyzed, 4,427 of which were eligible for analysis of the evolution of cervical abnormalities. Inprogression and regression events analysis, we observed that patients with a cytological diagnosis of atypical glandularcells presented a higher risk of cervical abnormality progression (Hazard Ratio: 2.0 and 95% confidence intervals1.36–3.48). We also observed that patients younger than 25 years old were more likely to regress the cervical lesions(Hazard Ratio:1.4 and 95% confidence intervals 1.20–1.74). Conclusions: The associations found between the events(progression and regression), age and cytological diagnosis, highlights the importance of cytological screening inpopulations at risk of precursor of cervical cancer lesions, especially in women older than 25 years.

2 January 2023 in Journal of Molecular Pathology
Verified
Journal Article
Open access
PDF file
ARAngela Della’santa Rubio O. Rönnau
Angela Della’santa Rubio O. Rönnau
MBMaiquidieli Dal Berto
Maiquidieli Dal Berto
CBClaudia Bica
Claudia Bica
RARafael José Vargas Alves
Rafael José Vargas Alves
LRLiane Rotta
Liane Rotta
Ratios between the blood cells are indirect measures of the imbalance in the pro-inflammatory status observed in carcinogenesis and have been proposed as accessible and feasible biomarkers to predict cancer prognosis. We aim to evaluate the prognostic significance of neutrophil/lymphocyte (NLR), monocyte/lymphocyte (MLR), and platelet/lymphocyte (PLR) ratios in Brazilian patients with luminal breast cancer (LBC) treated with tamoxifen. A retrospective cohort of 72 operable LBC patients. Preoperative leukocyte and platelet absolute values permitted to calculate NLR, MLR, and PLR. Area under curve (ROC) determined the cutoff value associated with relapse and death. Univariate and multivariate analyses were used to assess the relationship of the platelet and PLR to disease-free survival (DFS) and overall survival (OS). Lower DFS was associated with >297 × 103/mm3 (54 vs. 60.9 months in 279 × 103/mm3 are related to higher OS (p = 0.03). Univariate analysis revealed that platelet concentration was associated with DFS (p = 0.04) and OS (p = 0.04), but not as an independent factor (HR = 1.31, 95%CI: 0.42–4.07, p = 0.65) and OS (HR = 1.64, 95%CI: 0.28–9.52, p = 0.58). Both univariate (p = 0.01) and multivariate analysis revealed that PLR < 191.5 was a significant independent predictor of higher OS/better prognosis (HR = 16.16, 95%CI: 2.83–109.25, p = 0.00). Pretreatment platelet indices (absolute count and PLR) are prognosis predictors in LBC patients. Platelet > 279 × 103/mm3 and PRL < 191.5 was associated with a higher OS, with the PRL being an independent predictor of higher OS.

1 October 2021 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MBMaiquidieli Dal Berto
Maiquidieli Dal Berto
GSGiovana Tavares dos Santos
Giovana Tavares dos Santos
ASAniúsca Vieira dos Santos
Aniúsca Vieira dos Santos
ASAndrew Oliveira Silva
Andrew Oliveira Silva
JVJosé Vargas
José Vargas
CBClaudia Bica
Claudia Bica
Tamoxifen (TMX) is used as adjuvant therapy for estrogen receptor-positive (ER+) breast cancer cases due to its affinity and inhibitory effects. However, about 30% of cases show drug resistance, resulting in recurrence and metastasis, the leading causes of death. A literature review can help to elucidate the main cellular processes involved in TMX resistance. A scoping review was performed to find clinical studies investigating the association of expression of molecular markers profiles with long-term outcomes in ER+ patients treated with TMX. In silico analysis was performed to assess the interrelationship among the selected markers, evaluating the joint involvement with the biological processes. Forty-five studies were selected according to the inclusion and exclusion criteria. After clustering and gene ontology analysis, 23 molecular markers were significantly associated, forming three clusters of strong correlation with cell cycle regulation, signal transduction of proliferative stimuli, and hormone response involved in morphogenesis and differentiation of mammary gland. Also, it was found that overexpression of markers in selected clusters is a significant indicator of poor overall survival. The proposed review offered a better understanding of independent data from the literature, revealing an integrative network of markers involved in cellular processes that could modulate the response of TMX. Analysis of these mechanisms and their molecular components could improve the effectiveness of TMX.